Skip to main content

The BioPharma Dive Outlook on 2022

After surging into 2021, biotech crashed at the end of last year amid negative clinical trial readouts, ebbing M&A and broader investor pullback. But the year ahead figures to be busy on several fronts and a slate of important studies could deliver good news. 

included in this trendline
  • What clinical trials to watch in the first half of the new year
  • The most important questions facing the FDA
  • The top questions facing gene therapy this year
Note: Trendlines are a premium product, available to subscribers of our free newsletters. Access this Trendline by signing up for the BioPharma Dive newsletter or enter your information if you're already subscribed.
Produced by our team of award-winning journalists, the BioPharma Dive Outlook for 2022 can help you and your organization navigate the uncertain road ahead in your market.
Davide Savenije Editor-in-Chief at Industry Dive.